Pulmocide stops IPA trial after higher mortality rate in treated patients
Pulmocide will evaluate unblinded data from the Phase III trial to determine its next steps with the drug.
09 January 2026
09 January 2026
Pulmocide will evaluate unblinded data from the Phase III trial to determine its next steps with the drug.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.